Skip to main content
OpenTrials

Clinical trial condition

Cutaneous T Cell Lymphoma

Explore clinical trials studying Cutaneous T Cell Lymphoma. Study availability and eligibility vary by location and protocol.

31 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Cutaneous T Cell Lymphoma trial results

Completed

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

NCT02576496

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Cutaneous T Cell Lymphoma, +23 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • Mayo Clinic Cancer Center Jacksonville, Florida, United States
  • Columbia University Medical Center New York, United States
  • University Hospitals Cleveland Seidman Cancer Center Cleveland, Ohio, United States
View all 18 locations
View Trial Details
Completed

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

NCT03292406

Conditions
Cutaneous T Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Galderma Investigational Site Orange, California, United States
  • Galderma Investigational Site Palo Alto, California, United States
  • Galderma Investigational Site Farmington, Connecticut, United States
  • Galderma Investigational Site Chicago, Illinois, United States
View all 21 locations
View Trial Details
Completed

Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

NCT00221039

Conditions
Cutaneous T Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Rush-Presbyterian Hospital Chicago, Illinois, United States
  • Boston Medical Center Boston, Massachusetts, United States
  • University of Minnesota Minneapolis, Minnesota, United States
  • University Hospital of Cleveland/Case Western Reserve University Cleveland, Ohio, United States
View Trial Details
Completed

Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma

NCT00007345

Conditions
Cutaneous T Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Mayo Clinic Scottsdale Scottsdale, Arizona, United States
  • University of Arkansas Little Rock, Arkansas, United States
  • City of Hope National Cancer Center Duarte, California, United States
  • Mercy General Hospital Sacramento, California, United States
View all 13 locations
View Trial Details
Completed

RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas

NCT01198665

Conditions
Anaplastic Large Cell Lymphoma, ALK-negative, Angioimmunoblastic T Cell Lymphoma, Cutaneous T Cell Lymphoma, +15 more
Locations
  • National Cancer Center Goyang-si, Kyoungki-do, South Korea
  • Samsung Medical Center Seoul, South Korea
  • Asan Medical Center Seoul, South Korea
  • Korea Cancer Center Hospital Seoul, South Korea
View Trial Details

Related conditions